Salute e Benessere

Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate…

Together, Seegene and Springer Nature launched 'Nature Awards MDx Impact Grants in partnership with Seegene', a new project for the development of diagnostic assays. The program empowers researchers worldwide to develop innovative diagnostic assays using Seegene's advanced multiplex PCR technology. Together, Seegene and Springer Nature launched 'Nature Awards MDx Impact Grants in partnership with Seegene', a new project for the development of diagnostic assays. The program empowers…
PR Newswire
02/09/2024

Global Heart Hub's Insights from Patients living with Elevated Cholesterol…

Participants have highlighted the importance of personalised care plans in managing hypercholesterolemia. Using simple language and clear explanations of the risks associated with unmanaged LDL-C cholesterol level encourages patients to take their health seriously. A collaborative and supportive approach between HCPs and patients is needed to develop care plans, considering individual circumstances and lifestyle factors, ensuring realistic and measurable goals. Discussions on treatment options…
PR Newswire
02/09/2024

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK…

TGRX-326 is a third-generation anaplastic lymphoma kinase (ALK) inhibitor independently developed by TargetRx. It is a potent and highly selective small molecule inhibitor that targets ALK and c-ROS proto-oncogene 1 (ROS1) receptor tyrosine kinases (RTKs). This inhibitor holds significant therapeutic potential for ALK/ROS1 fusion gene-positive non-small cell lung cancer (NSCLC) patients, especially those with multiple ALK-resistant mutations, including G1202R. TGRX-326 is a third-generation...
PR Newswire
02/09/2024

Trading in GN Store Nord shares by board members, executives and associated…

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associated NameJukka Pekka Pertola Reason for the notification Position/statusChair of the Board of DirectorsInitial...
Nasdaq GlobeNewswire
02/09/2024

Buyback of Class B shares in Essity during week 35, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
02/09/2024

New US Consensus Report supports Nevisense

"I am so excited that this renowned panel of leading dermatologists has endorsed Nevisense as an important tool for early detection of melanoma. This is a significant step forward for SciBase in our US commercialization process," says Pia Renaudin, CEO of SciBase. " I am so excited that this renowned panel of leading dermatologists has endorsed Nevisense as an important tool for early detection of melanoma. This is a significant step forward for SciBase in our US commercialization…
PR Newswire
02/09/2024

Myocene Helps the French Handball Team

The innovative device developed by Myocene represents a radical change in the management of fatigue and recovery in sportspeople, making it possible for the first time to quantify it objectively and very precisely. It calculates the exact value of the muscular fatigue index in two minutes. The solution uses a dedicated algorithm to analyze very precise measurements obtained using a specific sensor and high-precision control of muscle contraction. It can be used both indoors and out, helping...
Nasdaq GlobeNewswire
02/09/2024

PCI Biotech: Employee share option scheme

In accordance with the authorisation granted by the Annual General Meeting 24 May 2024 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 885,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech's choice), at a strike price of NOK 1.81, equal to the volume weighted average share price (VWAP)...
Nasdaq GlobeNewswire
02/09/2024

Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study…

Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES study, tolebrutinib met the primary endpoint in delaying time to onset of confirmed disability progression in people with nrSPMS, a population for which there are currently no approved therapies and significant unmet medical needThe GEMINI 1 and 2 studies evaluating tolebrutinib in...
Nasdaq GlobeNewswire
02/09/2024

New Study Demonstrates that SL-NAD+ delivers NAD+ into Cells

The results revealed several important findings: The results revealed several important findings: Dr. Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer of iX Biopharma, said: "This study's findings provide strong evidence that our innovative sublingual freeze-dried technology delivers NAD+ rapidly into plasma and then directly into cells, challenging the previously held belief that its large size prevents cellular penetration. Along with the positive data from…
PR Newswire
02/09/2024

LG PRESENTS NEW APPLIANCE LINEUP WITH INDUSTRY-LEADING ENERGY EFFICIENCY AT IFA…

Industry-Leading Energy Efficiency with AI-Enhanced Laundry SolutionsLG's latest washing machine and dryer set new standards for energy efficiency. The washing machine is able to perform a new drum motion that helps deliver clean laundry while minimizing the energy consumption of its Artificial Intelligence Direct Drive (AI DD™) motor. The washer intelligently adjusts the motor's RPM in real-time, contributing to the appliance's impressive A-55 percent energy rating1 and preventing laundry from…
PR Newswire
02/09/2024

Avance Clinical GlobalReady Site Partnership Network Expands Rapidly to 2,000…

GlobalReady Site Partnership Network. Avance Clinical CEO, Yvonne Lungershausen said these 2,000 highly qualified sites further enhanced delivery of unprecedented efficiency and effectiveness for our biotech clients during their clinical development.Tina Schied, Avance Clinical's US-based Senior Site Specialist said the team has individually reviewed these sites for quality, therapeutic area expertise, advanced processes, and compliance so our clients can be assured of quality, rapid...
Nasdaq GlobeNewswire
01/09/2024

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief…

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt diseaseSAN DIEGO, Sept.01, 2024(GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced...
Nasdaq GlobeNewswire
01/09/2024

Junshi Biosciences Announces 2024 Interim Financial Results and Provides…

FINANCIAL HIGHLIGHTSAs of June 30, 2024, the total revenue of Junshi Biosciences was approximately RMB786 million during the first half of 2024, representing an increase of approximately 17% compared to 2023. The growth was mainly due to the approximately 11% increase in revenue from pharmaceutical products compared to 2023. In particular, the domestic sales revenue of our core product, TUOYI ®(toripalimab), reached approximately RMB671 million, representing an increase of...
Nasdaq GlobeNewswire
31/08/2024

Global Anti-Infective Drugs Market is Projected to Cross ~USD 175 Billion by…

Key Takeaways from the Anti-Infective Drugs Market Report Key Takeaways from the Anti-Infective Drugs Market Report To read more about the latest highlights related to the anti-infective drugs market, get a snapshot of the key highlights entailed in theGlobal Anti-Infective Drugs Market Report Anti-Infective Drugs Overview Anti-infective drugs are a broad category of medications designed to combat infections caused by pathogens such as bacteria, viruses, fungi, and parasites...
PR Newswire
30/08/2024

ALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future…

Key Takeaways from the ALK Inhibitors Market Report Key Takeaways from the ALK Inhibitors Market Report Discover which therapies are expected to grab the ALK inhibitors market share @ALK Inhibitors Market Report ALK Inhibitors Market Dynamics The market dynamics for ALK inhibitors have been evolving rapidly, driven by significantadvances in cancer treatment and the growing prevalence of ALK-positive cancers, particularly NSCLC. One of the primary drivers of the ALK...
PR Newswire
30/08/2024

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for…

"Today's authorization enables Novavax to launch our updated COVID-19 vaccine in the U.S. in pre-filled syringes, and we have worked hard to ensure consumers have access in thousands of locations nationwide," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Our updated vaccine targets JN.1, the 'parent strain' of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1."…
PR Newswire
30/08/2024

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 43 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August 30, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or...
Nasdaq GlobeNewswire
30/08/2024

Fagron's share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 August 2024 – 6PM CET Fagron's share buy-back program: Weekly update In the period from 26 August 2024 through 30 August 2024, Fagron purchased 37,000 of its own shares at an average price of € 18.99 per share corresponding to a total amount of € 1,357,476.41. These purchases are part of the share buy-back program of up to 150,000 Fagron shares to fulfill Fagron's obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
30/08/2024

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 30082024_trading_in_shares_PRM
Nasdaq GlobeNewswire
30/08/2024

Total number of shares and voting rights in Zealand Pharma on August 30, 2024

Company announcement – No. 42 / 2024 Total number of shares and voting rights in Zealand Pharma on August 30, 2024 Copenhagen, Denmark, August 30, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the...
Nasdaq GlobeNewswire
30/08/2024

Momcozy Concludes Successful Breastfeeding Month Campaign: 'Breaking…

At the heart of the campaign was the offline bus tour in partnership with Pumpspotting on Barb the Breast Express. This tour made multiple stops in communities, facilitating direct interactions with mothers. Discussions on breastfeeding challenges, giveaways, and engaging activities were organized to support and uplift mothers along their journeys. At the heart of the campaign was the offline bus tour in partnership with Pumpspotting on Barb the Breast Express. This tour made multiple stops…
PR Newswire
30/08/2024

Bioactive Dressings Market worth $5.8 billion by 2029 driven by Increasing Tech…

Browse in-depth TOC on "Bioactive Dressings Market" Browse in-depth TOC on "Bioactive Dressings Market" 439 - Tables57 - Figures343 - Pages Smith+Nephew: Global Leader in Bioactive Dressings Smith+Nephew (UK) held the top position in the bioactive dressings market in 2023, driven by a robust global distribution network acrossNorth America,Europe,Asia Pacific,Latin America, theMiddle East, andAfrica. This wide geographical presence enables the company...
PR Newswire
30/08/2024

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 30082024_trading_in_shares_ARA
Nasdaq GlobeNewswire
30/08/2024
Altri  Comunicati